Michel Pierre Rose Berthelin, the EVP of $ADNT, sold 2,500 shares of the company on 11-26-2025 for an estimated $49,275. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.1% of their shares of this class of stock. Following this trade, they now own 116,425 shares of this class of $ADNT stock.
$ADNT Insider Trading Activity
$ADNT insiders have traded $ADNT stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ADNT stock by insiders over the last 6 months:
- JEROME J. DORLACK (President and CEO) sold 12,000 shares for an estimated $273,240
- MICHEL PIERRE ROSE BERTHELIN (EVP, EMEA) sold 2,500 shares for an estimated $49,275
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ADNT Hedge Fund Activity
We have seen 126 institutional investors add shares of $ADNT stock to their portfolio, and 171 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 1,839,894 shares (-27.0%) from their portfolio in Q3 2025, for an estimated $44,304,647
- GOLDMAN SACHS GROUP INC added 1,140,714 shares (+102.6%) to their portfolio in Q3 2025, for an estimated $27,468,393
- PACER ADVISORS, INC. removed 1,124,978 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $21,892,071
- QUANTEDGE CAPITAL PTE LTD added 1,036,111 shares (+4317.1%) to their portfolio in Q3 2025, for an estimated $24,949,552
- BLACKROCK, INC. removed 953,103 shares (-6.0%) from their portfolio in Q3 2025, for an estimated $22,950,720
- ASSENAGON ASSET MANAGEMENT S.A. added 732,837 shares (+921.9%) to their portfolio in Q3 2025, for an estimated $17,646,714
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 718,538 shares (+61.3%) to their portfolio in Q3 2025, for an estimated $17,302,395
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ADNT Analyst Ratings
Wall Street analysts have issued reports on $ADNT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 11/06/2025
- Wells Fargo issued a "Overweight" rating on 09/25/2025
- B of A Securities issued a "Underperform" rating on 09/10/2025
- Morgan Stanley issued a "Underweight" rating on 08/12/2025
To track analyst ratings and price targets for $ADNT, check out Quiver Quantitative's $ADNT forecast page.
$ADNT Price Targets
Multiple analysts have issued price targets for $ADNT recently. We have seen 9 analysts offer price targets for $ADNT in the last 6 months, with a median target of $22.5.
Here are some recent targets:
- Michael Ward from Citigroup set a target price of $22.5 on 11/12/2025
- Dan Levy from Barclays set a target price of $24.0 on 11/07/2025
- Ryan Brinkman from JP Morgan set a target price of $24.0 on 11/06/2025
- Nathan Janes from Stifel set a target price of $24.0 on 11/06/2025
- Colin Langan from Wells Fargo set a target price of $28.0 on 11/06/2025
- Joseph Spak from UBS set a target price of $22.0 on 11/06/2025
- Federico Merendi from B of A Securities set a target price of $20.0 on 09/10/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
